PROK2、HRNR和FIG4可作为东亚ACS患者替格瑞洛高出血倾向的潜在遗传生物标志物
本多中心前瞻性队列研究纳入208例接受替格瑞洛治疗的东亚ACS患者,随访12个月,通过全外显子测序检测SNP。发现15个基因的22个SNP与累积出血事件显著相关,其中FIG4 rs2295837、PROK2 rs3796224和HRNR rs6662450分别与1、6、12个月出血风险最强相关。
要点
- FIG4 rs2295837 T等位基因携带者1个月内出血风险增加(OR 3.07)。
- PROK2 rs3796224 T等位基因携带者6个月内出血风险增加(OR 2.16)。
- HRNR rs6662450 T等位基因携带者12个月内出血风险降低(OR 0.48)。
核心结论
- 包括PROK2、HRNR和FIG4在内的15个基因是东亚ACS患者使用替格瑞洛后高出血倾向的潜在生物标志物。
研究设计与样本
- 多中心前瞻性队列研究,纳入2018年3月至2021年7月4个分中心医院的208例接受替格瑞洛治疗并接受基因检测的ACS患者。
主要发现
- 96.60%的患者接受替格瑞洛联合阿司匹林或西洛他唑治疗,42.3%的患者在12个月随访期间发生出血事件。
- 全外显子测序发现15个基因的22个SNP与1、6、12个月累积出血事件显著相关(p<0.01)。
- FIG4 rs2295837(A>T)与1个月内出血事件关联最强(p=1.28×10-4),T等位基因携带者出血风险增加(OR 3.07,95%CI 1.68-5.63)。
- PROK2 rs3796224(C>T)与6个月内累积出血事件关联最强(p=4.57×10-4),T等位基因携带者出血风险增加(OR 2.16,95%CI 1.20-3.89)。
- HRNR rs6662450(C>T)与12个月内累积出血事件关联最强(p=4.86×10-4),T等位基因携带者出血风险降低(OR 0.48,95%CI 0.24-0.95)。
临床怎么用
- 对于接受替格瑞洛治疗的东亚ACS患者,可考虑检测FIG4 rs2295837、PROK2 rs3796224和HRNR rs6662450以辅助评估出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: East Asians have a higher risk of bleeding than Europeans when treated with ticagrelor. This study aimed to explore genetic indicators related to the high bleeding propensity in East Asian patients with acute coronary syndrome (ACS) using ticagrelor. DESIGN: A multicenter prospective cohort study. SETTING: Four sub center hospitals participating the study. PATIENTS: Between March 2018 and July 2021, 208 patients with ACS were administered ticagrelor and underwent genetic testing. INVERTENTION: Patients were enrolled and followed up for bleeding events for 12 months. Single-nucleotide polymorphisms (SNPs) were detected using whole-exome sequencing. SNPs significantly associated with cumulative bleeding events within 1-, 6-, and 12-month follow-ups were selected (p < 0.01). Among these, SNPs showing a difference of ≥2 fold in their distribution frequency among East Asians and Europeans were selected. MEASUREMENTS AND MAIN RESULTS: Among all patients, 96.60% received ticagrelor plus aspirin or cilostazol, and 42.3% suffered from bleeding events during 12-month follow-up. Furthermore, 22 SNPs of 15 genes were found to have a significant association with cumulative bleeding events within 1-, 6-, and 12-month follow-ups. Among these SNPs, FIG4 rs2295837 (A>T) variant had the strongest association with bleeding events within 1 month (p = 1.28 × 10-4 ), with an increased risk of bleeding in T allele carriers (odds ratio [OR]: 3.07, 95% confidence interval [CI]: 1.68-5.63). PROK2 rs3796224 (C>T) variant was most strongly associated with cumulative bleeding events within 6 months (p = 4.57 × 10-4 ) with an increased risk of bleeding in T allele carriers (OR: 2.16, 95% CI: 1.20-3.89). Moreover, HRNR rs6662450 (C>T) variant showed the strongest relation with cumulative bleeding events within 12 months (p = 4.86 × 10-4 ) with a reduced risk of bleeding in T allele carriers (OR: 0.48, 95% CI: 0.24-0.95). CONCLUSION: Fifteen genes, including PROK2, HRNR, and FIG4, were potential biomarkers of high bleeding propensity in East Asian patients with ACS using ticagrelor.
引用
- Xiang Q, Wang Z, Mu G, et al. PROK2, HRNR, and FIG4 as potential genetic biomarkers of high bleeding propensity in East Asian patients with acute coronary syndrome using ticagrelor. Pharmacotherapy. 2022. PMID: 36263704. doi:10.1002/phar.2736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。